After strong gains last year, biotech stocks are underperforming YTD despite a record wave of M&A activity fueled in part by ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

Biotech Beyond Borders Report finds that the biotech industry is grappling with a wave of challenges, including ongoing ...

Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

This Biotech Stock Is Up 85%. FDA Has Agreed to Review a Skin Cancer Drug. Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced ...

Treeline Biosciences, a well-funded cancer company that has raised more than $1 billion since its 2021 founding, is looking ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...